A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

NCT05591079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

OTHER

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG: CS0159 (Linafexor)

Sponsor

Cascade Pharmaceuticals, Inc

Collaborators

[object Object]